Search

Your search keyword '"Koura, Divya"' showing total 23 results

Search Constraints

Start Over You searched for: Author "Koura, Divya" Remove constraint Author: "Koura, Divya" Database Unpaywall Remove constraint Database: Unpaywall
23 results on '"Koura, Divya"'

Search Results

1. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

2. Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

3. Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).

4. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

5. NCCN Guidelines® Insights: Survivorship, Version 1.2023

6. P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS

9. Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

10. NCCN Guidelines® Insights: Survivorship, Version 1.2022

11. A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-Free Graft-Versus-Host Disease Prophylaxis Regimen with Post-Transplantation Cyclophosphamide and Abatacept to Standard of Care

12. Survivorship, Version 1.2021

14. NCCN Guidelines Insights: Survivorship, Version 2.2020

16. NCCN Guidelines Insights: Survivorship, Version 2.2019

18. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

19. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

20. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire

21. Exhaustive TCR Deep Sequencing Reveals That CMV Reactivation Fundamentally Resets Immune Reconstitution after Transplant and Results in Significant Deficits in the Effector Memory TCR Repertoire

22. In Vivo T Cell Costimulation Blockade with Abatacept for Acute Graft-versus-Host Disease Prevention: A First-in-Disease Trial

Catalog

Books, media, physical & digital resources